Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics

19 Apr 2023

Abstract excerpt

(1) Background: The oncology field has drastically changed with the advent of precision medicine, led by the discovery of druggable genes or immune targets assessed through next-generation sequencing. Biomarker-based treatments are increasingly emerging, and currently, six tissue-agnostic therapies are FDA-approved. (2) Methods: We performed a review of the literature and reported the trials that led to the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Cancer Immunotherapy and Biomarkers
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37111371
DOI: 10.3390/ph16040614

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right GenomicsPMID 37111371Read ↗

Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications.Semantic proximity Read ↗

Target-Driven Tissue-Agnostic Drug Approvals; a New Path of Drug DevelopmentSemantic proximity Read ↗

From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm.Semantic proximity Read ↗

Tissue-Agnostic Drug Development: A New Path to Drug ApprovalSemantic proximity Read ↗

Harnessing tumor-agnostic biomarkers for precision medicine in lymphoma.Semantic proximity Read ↗

Tumor-Type Agnostic, Targeted Therapies: BRAF Inhibitors Join the Group.Semantic proximity Read ↗

Impact of tissue-agnostic approvals for patients with gastrointestinal malignanciesSemantic proximity Read ↗

If it's a target, it's a pan-cancer target: Tissue is not the issue.Semantic proximity Read ↗

First Tissue-Agnostic Drug Approval IssuedSemantic proximity Read ↗

[Histology-agnostic tumor treatment - a farewell to tumor entities?]Semantic proximity Read ↗

Advances in Precision Oncology: From Molecular Profiling to Regulatory-Approved Targeted TherapiesSemantic proximity Read ↗

Tumor-Specific and Tumor-Agnostic Molecular Signatures Associated With Response to Immune Checkpoint Inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.